Results 161 to 170 of about 44,698 (301)
1369 CD64-directed scFv fusion protein exhibits cytotoxicity and is a tool for site-specific diagnosis of acute myeloid leukemia [PDF]
, 2022 Siew Leng Tai +3 more
openalex +1 more source
Engineering, Expression, Purification, and Application of Glycosaminoglycan‐Specific Antibodies
Current Protocols, Volume 6, Issue 5, May 2026.Abstract Cluster of differentiation markers have been transformative for defining cell populations and their functional states, but recent work indicates that finer granularity can be achieved by considering the diverse heparan sulfate structures presented on proteoglycans.
Kheerthana Duraivelan +7 more
wiley +1 more source
MOESM1 of Recombinant production of the antibody fragment D1.3 scFv with different Bacillus strains
, 2017 Antonia Lakowitz +2 more
openalex +1 more source
Current Protocols, Volume 6, Issue 5, May 2026.Abstract Developing protein interaction–based technologies such as biosensors requires a clear understanding of receptor‐target kinetics. Nanobodies, which are camelid‐derived single‐domain antibodies, are ideal biosensor receptors due to their high specificity, stability, and ease of production. During biosensor development, multiple nanobody variants
Escarlet Díaz‐Galicia +5 more
wiley +1 more source
In vivo CAR therapies: Turning the patient into their own CAR factory
HemaSphere, Volume 10, Issue 5, May 2026.Abstract Over the past decade, ex vivo autologous chimeric antigen receptor (CAR)‐T‐cell therapies have reshaped the treatment of B‐cell malignancies. Despite their remarkable clinical efficacy, their application remains limited by complex manufacturing processes, demanding logistics, long turnaround times, and substantial costs. In vivo CAR approaches
François Vilcot +3 more
wiley +1 more source
Development of CAR Exosomes Targeting FAP for the Treatment of Intrauterine Adhesion
Journal of Extracellular Vesicles, Volume 15, Issue 5, May 2026.ABSTRACT Engineered extracellular vesicles (EVs) have emerged as promising cell‐free platforms for immunomodulation and tissue repair. In this study, we generated EVs derived from chimeric antigen receptor (CAR) T cells targeting fibroblast activation protein (FAP) and investigated their biological and therapeutic functions.
Wenyan Fu +8 more
wiley +1 more source
CAR‐T Cells: Current Status, Challenges, and Future Prospects
MedComm, Volume 7, Issue 5, May 2026.This graphical abstract outlines the current status, challenges, and future prospects of CAR‐T cells. The biological basis of CAR‐T cell therapy is the elegant redirection of adaptive immunity. Its initial successes have exposed a landscape of multifaceted challenges.
Aya Sedky Adly +6 more
wiley +1 more source
Development of CAR NK Cell Lines Selectively Targeting Cancer Cells Expressing Membrane Hsp70
MedComm, Volume 7, Issue 5, May 2026.This work presents a novel CAR NK cell platform targeting membrane‐bound Hsp70, a tumor‐specific antigen broadly expressed on solid tumors but not on normal cells. Computational modeling confirmed strong binding between the CAR construct and the Hsp70‐derived TKD peptide.
Khouloud Hachani +17 more
wiley +1 more source
CD24 in Melanoma: Biomarker, Innate Immune Checkpoint and Emerging Therapeutic Target
Experimental Dermatology, Volume 35, Issue 5, May 2026.ABSTRACT Immune checkpoint inhibitors have transformed the treatment of advanced melanoma, yet many patients develop primary or acquired resistance. Although most work has focused on adaptive checkpoints (PD‐1 and CTLA‐4), accumulating evidence implicates innate immune suppression and stem‐like, drug‐resistant melanoma cell states.
Claudia Lasalle +6 more
wiley +1 more source